Liminatus Pharma provides IBA101 strategic update targeting PD-1/L1 patent cliff partnership opportunities

Liminatus Pharma, Inc.

IBA101 is a CD47 mAb designed to avoid RBC/platelet binding, eliminating cytopenia that derailed Hu5F9 and lemzoparlimab.
Preclinical data shows IBA101 + anti-PD-1 combination produces synergistic anti-tumor response with favorable safety.
Company claims it is the only U.S.-based firm developing a CD47 blocker with a validated safety profile.
PD-1/L1 inhibitors Keytruda (Merck) and Opdivo (BMS) face core patent expiry by 2028; others (Tecentriq, Imfinzi, Libtayo) by 2030.
Strategy positions IBA101 as a patent-protected synergistic partner to extend PD-1/L1 franchise lifecycles.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.